{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-105818","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.443550+00:00","generated_at":"2026-05-17T00:30:40.913422+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Novavax completes U.S. marketing authorization transfer to Sanofi for Nuvaxovid, earns $25M milestone","bullets":["FDA approved transfer of U.S. marketing authorization for Nuvaxovid from Novavax to Sanofi on Nov 3, 2025.","Second $25M milestone payment triggered; follows EU transfer in Oct 2025. Payment expected Q1 2026.","Total non-dilutive capital secured YTD 2025 from Sanofi milestones is $225M.","Sanofi now responsible for U.S. commercial and regulatory activities for Nuvaxovid.","CEO John C. Jacobs notes delivery on partnership obligations and future royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-105818","json":"https://secwatch.observer/filing/0001104659-25-105818.json","markdown":"https://secwatch.observer/filing/0001104659-25-105818.md","text":"https://secwatch.observer/filing/0001104659-25-105818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925105818/0001104659-25-105818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925105818/tm2530132d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:30:40.913422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}